Skip to main content
. 2017 Oct 5;8(10):e118. doi: 10.1038/ctg.2017.45

Table 2. Univariate and multivariate analysis of prognostic factors in ICC patients using the Cox’s proportional hazards model in training cohort (n=164).

Variable Category N Univariate analysis; overall survival
 Multivariate analysis; overall survival
      HR 95% CI P HR 95% CI P
Preoperative available factors
 Gender Male 99 1.3 0.797–2.122 0.293 / / /
  Female 65            
 Age ≤60 77 0.866 0.542–1.385 0.548 / / /
  >60 87            
 CRP (mg/l) ≤4.1 105 2.74 1.707–4.399 <0.0001 2.45 1.40–4.30 P=0.002
  >4.1 59            
 NLRa ≤2.1 64 1.788 1.067–2.997 0.027 / / /
  >2.1 99            
 PLRb ≤190 137 1.798 1.012–3.192 0.045 / / /
  >190 26            
 CEAc (ng/ml) ≤4.5 111 2.747 1.652–4.567 P<0.0001 / / /
  >4.5 41            
 CA19-9d (ng/l) ≤300 118 3.064 1.83–5.13 P<0.0001 2.96 1.70–5.15 P<0.0001
  >300 36            
 ALBe (g/l) ≤40 70 1.163 0.465–2.904 P=0.747 / / /
  >40 90            
                 
Pathology factors
 Tumor size ≤5 75 2.199 1.326–3.648 0.002 / / /
  >5 89            
 Tumor number Single 137 2.09 1.232–3.544 0.006 2.37 1.31–4.29 0.004
  Multiple 27            
 Vascular invasion Present 21 2.349 1.3–4.242 0.005 2.04 1.01–4.13 0.048
  Absent 143            
 Perineural invasion Present 23 1.645 0.880–3.076 0.119 / / /
  Absent 141            
 Differentiationf Poor 16 1.189 0.816–1.732 0.367 / / /
  Moderate 68            
  Well 80            
 Lymph node metastasis Present 50 3.362 2.075–5.450 <0.001 3.06 1.76–5.33 <0.0001
  Absent 114            
 Cirrhosis Present 39 0.885 0.506–1.548 0.668 / / /
  Absent 125            
 TNMg 1 (0.I, II) 106 2.214 1.326–3.697 0.002 / / /
  2 (III, IVa) 58            

Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; CRP, C-reactive protein; HbsAg, hepatitis B surface antigen; HR, hazard ratio; ICC, intrahepatic cholangiocarcinoma; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; TNM, tumor node metastasis.

a

Missing data: n=1 (due to missing NLR value in training cohort, n=1).

b

Missing data: n=1 (due to missing PLR value in training cohort, n=1).

c

Missing data: n=12 (due to missing CEA value in training cohort, n=12).

d

Missing data: n=10 (due to missing CA19-9 value in training cohort, n=10).

e

Missing data: n=4(due to missing ALB value in training cohort, n=4).

f

Tumor differentiation was determined according to the British Society of Gastroenterology guidelines on the management of cholangiocarcinoma.

g

TNM: American Joint Committee on Cancer 7th edition staging for intrahepatic cholangiocarcinoma.